Related Experiment Video

Updated: Aug 14, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

EphA2 as a target for ovarian cancer therapy

Charles N Landen1, Michael S Kinch, Anil K Sood

  • 1Department of Gynecologic Oncology, U.T.M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Expert Opinion on Therapeutic Targets
|November 23, 2005
PubMed

Insights

Targeting EphA2 receptor tyrosine kinase, overexpressed in many cancers like ovarian cancer, can inhibit tumor growth and metastasis. EphA2 downregulation shows promise for effective cancer therapies, especially with taxanes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • EphA2 receptor tyrosine kinase is overexpressed in numerous human cancers, correlating with poor prognosis.
  • EphA2 plays a critical role in malignant progression, including cancer cell migration, invasion, metastasis, proliferation, survival, and angiogenesis.

Purpose of the Study:

  • To evaluate the therapeutic potential of targeting EphA2 in preclinical cancer models.
  • To investigate the efficacy of EphA2 downregulation as a strategy for cancer treatment, particularly in ovarian cancer.

Main Methods:

  • EphA2 downregulation was induced using antibody-mediated inhibition of signaling, antibody-mediated downregulation of total EphA2 expression, and siRNA-mediated inhibition of expression.
  • Therapeutic efficacy was assessed in preclinical models of ovarian, breast, and pancreatic cancer.

Main Results:

  • Inducing EphA2 downregulation significantly decreased tumor growth, prolonged survival, and inhibited angiogenesis in preclinical models.
  • EphA2 targeting demonstrated particular efficacy in ovarian cancer, where it is overexpressed in over 75% of cases.
  • EphA2 inhibition showed enhanced effectiveness when combined with taxanes in ovarian cancer models.

Conclusions:

  • Targeting EphA2 is a promising therapeutic strategy for various cancers, especially ovarian cancer.
  • The low expression of EphA2 in normal tissues and lack of preclinical toxicity suggest its potential for long-term therapeutic use.
  • Combination therapy with EphA2 inhibitors and taxanes represents an attractive approach for ovarian cancer treatment.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...